查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602720

肌萎缩侧索硬化症治疗药物市场：按治疗方法、分销管道划分 - 全球预测 2025-2030 年

Amyotrophic Lateral Sclerosis Treatment Market by Treatment (Medication, Stem Cell Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肌萎缩侧索硬化症治疗药物市场规模为73442万美元，预计2024年将达到79052万美元，复合年增长率为7.73%，到2030年预计将达到123705万美元。

肌萎缩侧索硬化症 (ALS) 治疗市场研究对各种治疗解决方案进行了全面分析，旨在管理 ALS 症状、减缓疾病进展并改善患者的生活品质。 ALS 的严重性强调了对 ALS 治疗的需求，目前尚无明确的治疗方法，这推动了对创新治疗方法的迫切需求。治疗通常涉及新的多学科方法，包括神经保护药物、物理治疗以及遗传和干细胞研究。该市场受到生物技术进步、神经学研究资金增加以及人口老化导致 ALS 患者患病率增加等因素的影响。关键的成长机会在于个人化医疗和基因治疗，这些领域可以透过生技公司和研究机构之间的策略联盟来发展。他们还应该考虑透过进入亚洲和南美洲开拓的市场来实现市场多元化，这些市场由于医疗基础设施和意识的改善，对创新治疗的兴趣正在增加。然而，市场成长面临挑战，包括高研发成本、高监管障碍以及疾病进展的不可预测性，这使得衡量治疗效果变得复杂。智慧财产权和仿单标示外药品的竞争进一步限制了竞争格局。根据市场动态，ALS治疗创新的未来取决于CRISPR技术和生物标记研究的突破，这将显着提高早期检测和治疗的准确性。寻求成长的相关人员应大力投资于科学合作和以病人为中心的照护模式，以适应向个人化治疗方法的典范转移。了解市场的性质表明，患者的宣传和教育将在重塑治疗的采用和接受方面发挥关键作用。总之，儘管监管环境仍然复杂，但优先考虑研究和策略联盟敏捷性的公司将处于有利地位，可以抓住 ALS 治疗市场的新机会。

主要市场统计
基准年[2023] 7.3442亿美元
预测年份 [2024] 79052万美元
预测年份 [2030] 1,237.05 百万美元
复合年增长率（%） 7.73%

市场动态：快速发展的肌萎缩侧索硬化症药物市场的关键市场洞察

供需的动态交互作用正在改变肌萎缩侧索硬化症药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球有大量肌萎缩性侧索硬化症患者
    • 人们对 ALS 治疗的认知不断增强
  • 市场限制因素
    • ALS 治疗相关的高成本
  • 市场机会
    • 活性化旨在开发新的 ALS 药物和治疗方法的研发
    • 改善各国的医疗基础设施
  • 市场挑战
    • ALS 治疗的严格核准流程

波特五力：驾驭肌萎缩侧索硬化症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肌萎缩侧索硬化症药物市场的外部影响

外部宏观环境因素在塑造肌萎缩侧索硬化症药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肌萎缩侧索硬化症治疗药物市场的竞争状况

对肌萎缩侧索硬化症治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵肌萎缩侧索硬化症药物市场供应商绩效评估

FPNV定位矩阵是评估肌萎缩侧索硬化症药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘肌萎缩侧索硬化症药物市场的成功之路

对肌萎缩侧索硬化症治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地有许多人患有肌萎缩性侧索硬化症。
      • 提高大众对 ALS 治疗的认识
    • 抑制因素
      • ALS 治疗相关的高费用
    • 机会
      • 加强研究活动，开发 ALS 新药和治疗方法
      • 改善整个经济领域的医疗基础设施
    • 任务
      • ALS 药物的严格核准流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肌萎缩侧索硬化症治疗药物市场（依治疗）

  • 药物治疗
    • Edaravone
    • Riluzole
  • 干细胞疗法

第七章肌萎缩侧索硬化症治疗药物市场：按分销管道

  • 医院药房
  • 零售药房

第八章北美和南美肌萎缩侧索硬化症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肌萎缩侧索硬化症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲肌萎缩侧索硬化症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AB Science SA
  • Amylyx Pharmaceuticals Inc.
  • Aquestive Therapeutics Inc.
  • Ascend Pharmaceuticals LLC
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Co Ltd
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • Cytokinetics, Incorporated
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals, LLC
  • Hackensack Meridian Health, Inc.
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Orion Corporation
  • Orphazyme A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi-Aventis Groupe SA
  • Sun Pharmaceutical Industries Ltd
  • Treeway BV
Product Code: MRR-AD36CD897F1B

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 734.42 million in 2023, expected to reach USD 790.52 million in 2024, and is projected to grow at a CAGR of 7.73%, to USD 1,237.05 million by 2030.

Amyotrophic Lateral Sclerosis (ALS) treatment market research encompasses a comprehensive analysis of various therapeutic solutions aimed at managing ALS symptoms, slowing disease progression, and improving patient quality of life. The necessity for ALS treatments is underscored by the severe nature of the disease, which currently lacks a definitive cure, prompting a critical demand for innovative therapies. Treatments typically include the use of neuroprotective drugs, physical therapies, and emerging multidisciplinary approaches that involve genetic and stem cell research. The market is influenced by factors such as advancements in biotechnology, increased funding for neurological research, and an aging population that elevates the prevalence of ALS cases. Key growth opportunities lie in personalized medicine and gene therapy, areas that can be leveraged through strategic partnerships between biotech firms and research institutions. Companies should also consider geographic diversification, tapping into underexplored markets in Asia and South America, where rising healthcare infrastructure and awareness are fostering a keen interest in innovative treatments. However, market growth faces challenges including high R&D costs, stringent regulatory hurdles, and the unpredictable nature of disease progression that complicates treatment efficacy measurement. Intellectual property rights and competition from off-label drugs further constrain the landscape. According to market dynamics, the future of ALS treatment innovation hinges on breakthroughs in CRISPR technologies and biomarker research, which could significantly enhance early detection and therapeutic precision. Stakeholders anticipating growth should heavily invest in scientific collaborations and patient-centric care models to align with the shifting paradigm toward personalized treatment approaches. Understanding market nature indicates that patient advocacy and education will play pivotal roles in reshaping treatment uptake and acceptance. In summary, while navigating regulatory landscapes remains complex, firms that prioritize agility in research and strategic alliances will better position themselves to capture emerging opportunities in the ALS treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 734.42 million
Estimated Year [2024] USD 790.52 million
Forecast Year [2030] USD 1,237.05 million
CAGR (%) 7.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyotrophic Lateral Sclerosis Treatment Market

The Amyotrophic Lateral Sclerosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant number of amyotrophic lateral sclerosis patients worldwide
    • Growing awareness about ALS treatment among population
  • Market Restraints
    • High cost associated with ALS treatments
  • Market Opportunities
    • Increasing research activities to develop novel ALS drugs and treatments
    • Improved healthcare infrastructure across economies
  • Market Challenges
    • Stringent approval processes for ALS therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Amyotrophic Lateral Sclerosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyotrophic Lateral Sclerosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyotrophic Lateral Sclerosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyotrophic Lateral Sclerosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyotrophic Lateral Sclerosis Treatment Market

A detailed market share analysis in the Amyotrophic Lateral Sclerosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyotrophic Lateral Sclerosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyotrophic Lateral Sclerosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyotrophic Lateral Sclerosis Treatment Market

A strategic analysis of the Amyotrophic Lateral Sclerosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyotrophic Lateral Sclerosis Treatment Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, Amylyx Pharmaceuticals Inc., Aquestive Therapeutics Inc., Ascend Pharmaceuticals LLC, Biogen Inc., Biohaven Pharmaceutical Holding Co Ltd, BrainStorm Cell Limited, Corestem, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche AG, Genervon Biopharmaceuticals, LLC, Hackensack Meridian Health, Inc., Implicit Bioscience Ltd., Ionis Pharmaceuticals, Inc., ITF Pharma, Inc., Kringle Pharma, Inc., Mitsubishi Tanabe Pharma Corporation, Orion Corporation, Orphazyme A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sun Pharmaceutical Industries Ltd, and Treeway B.V..

Market Segmentation & Coverage

This research report categorizes the Amyotrophic Lateral Sclerosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Medication and Stem Cell Therapy. The Medication is further studied across Edaravone and Riluzole.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant number of amyotrophic lateral sclerosis patients worldwide
      • 5.1.1.2. Growing awareness about ALS treatment among population
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with ALS treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research activities to develop novel ALS drugs and treatments
      • 5.1.3.2. Improved healthcare infrastructure across economies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval processes for ALS therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Edaravone
    • 6.2.2. Riluzole
  • 6.3. Stem Cell Therapy

7. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies

8. Americas Amyotrophic Lateral Sclerosis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AB Science SA
  • 2. Amylyx Pharmaceuticals Inc.
  • 3. Aquestive Therapeutics Inc.
  • 4. Ascend Pharmaceuticals LLC
  • 5. Biogen Inc.
  • 6. Biohaven Pharmaceutical Holding Co Ltd
  • 7. BrainStorm Cell Limited
  • 8. Corestem, Inc.
  • 9. Cytokinetics, Incorporated
  • 10. F. Hoffmann-La Roche AG
  • 11. Genervon Biopharmaceuticals, LLC
  • 12. Hackensack Meridian Health, Inc.
  • 13. Implicit Bioscience Ltd.
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. ITF Pharma, Inc.
  • 16. Kringle Pharma, Inc.
  • 17. Mitsubishi Tanabe Pharma Corporation
  • 18. Orion Corporation
  • 19. Orphazyme A/S
  • 20. Otsuka Pharmaceutical Co., Ltd.
  • 21. Pfizer Inc.
  • 22. Sanofi-Aventis Groupe S.A.
  • 23. Sun Pharmaceutical Industries Ltd
  • 24. Treeway B.V.

LIST OF FIGURES

  • FIGURE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023